Madrigal Pharma - MDGL Quarterly EPS earnings growth

Madrigal Corp - graphic logo of issuer MDGL

The quarterly EPS growth trajectory reflects market optimism, with the 135.70 value serving as the baseline indicator for Madrigal Pharmaceuticals (MDGL). This positive sentiment is driven by the establishment of robust distribution channels for new drugs and the recruitment of top specialists in liver pathology. The foundation for growth was laid by Rezdiffra, which became the first approved therapy for MASH, providing the company with an exceptional competitive advantage.

Madrigal Pharmaceuticals, Inc. (MDGL) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/17/2026

Financial and market metric breakdowns for Madrigal Pharmaceuticals (MDGL)

Analysis of all company metrics:Madrigal Pharmaceuticals
Manufactured product of Madrigal Corp

Professional capital evaluates Madrigal Pharmaceuticals (MDGL) through the monetization dynamics of its unique therapeutic advantages. This indicator measures the quarterly change in earnings per share, filtering out market noise to identify the true resilience of the business. By analyzing the quarterly EPS growth trend, investors can see the actual efficiency of capitalizing on the exclusive right to treat NASH. The lack of therapeutic alternatives ensures a steady cash flow, confirming the high fundamental reliability of the asset.

Competitors of Madrigal Pharmaceuticals (MDGL)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|CORT: Year-over-year earnings per share growth rate for the last twelve months|RYTM (Rhythm Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Akero Therapeutics|Quarterly EPS earnings growth MTSR|Year-over-year earnings per share growth for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Year-over-year earnings per share growth for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Earnings per share growth in annualized terms for the last twelve months|SLNO - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months rezolutebio.com (RZLT)|Year-over-year net earnings per share growth for the last 12 months lexpharma.com LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS